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Abstract
We present the results of a study in which biomolecular interaction analysis (BIA, Biacore™ 2000) 
was combined with Mass Spectrometry using entire “on-a-chip” procedure. Most BIA-MS studies 
included an elution step of the analyte prior MS analysis. Here, we report a low-cost approach 
combining Biacore analysis with homemade chips and MS in situ identification onto the chips without 
elution step. First experiments have been made with Rat Serum Albumin to determine the sensitivity 
and validation of the concept has been obtained with an antibody/antigen couple. Our “on-a-chip”
procedure allowed complete analysis by mass spectrometry (MS/MS2) of the biochip leading to
protein identifications at low femtomole to sub-femtomole levels. Using this technique, identification 
of protein complexes were routinely obtained giving the opportunity to the “on-a-chip” processing to 
complete the BIA-MS approach in the discovery and analysis of protein complexes.
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1. Introduction
Many cutting-edge technologies are available in proteomics but the combination of two or more 
technologies will help overcome major drawbacks in analytical methods. Some of these combinations 
such as liquid chromatography (LC) with mass spectrometry (MS) giving LC-MS and LC-MS-MS 
approaches are used routinely today. Recently, new methods combining biosensors with MS have 
been explored. Out scope of passive surface which provided no information on the biological events 
that occur at the surface of the chip, the last decade has seen an increasing interest in intelligent 
surfaces mainly based on surface plasmon resonance (SPR) which allow monitoring of biorecognitions
and captures in real time without any labeling (Nilsson et al, 1995; Nieba et al, 1997; Frederix et al., 
2003, Grosjean et al, 2005). Few groups have developed the combination of SPR devices with mass 
spectrometry leading to a new concept called BIA-MS for Biomolecular Interaction Analysis-Mass 
Spectrometry (Natsume et al., 2000; Nedelkov and Nelson, 2000; Lopez et al., 2003; Catimel et al., 
2005; Larsericsdotter et al., 2006, Bouffartigues et al., 2007). Briefly, this combination of instruments
has led to better global proteomic analysis by combining qualitative (kinetics of interactions) and 
quantitative (amount of bound proteins) information provided by SPR with the structural features of 
the proteins thanks to mass spectrometry. The first step of this analytical method provides intact 
proteins immobilized on a chip. The pro eins can then be analyzed further using MS, either directly on
the chip or after an elution step. The main approach deals with elution of bound materials which slow 
down the sensitivity. In order to overcome major drawbacks of this elution way (rate of eluted protein 
of interest, dilution of the sample, loss of materials and incompatibility between the elution buffer 
used and the mass spectrometry, reproducibility…), very few studies have explored direct digestion of 
the immobilized proteins, which are in situ analyzed using MS after SPR experiments (Grote et al., 
2005). From our knowledge, this approach has not been yet successfully explored and some
drawbacks must be overcome as the conception and realization of low cost SPR chips, the 
optimization of pre-treatments prior to mass spectrometry analysis, the global sensitivity of this 
approach. So, if the combination of SPR with MS has great potential in functional proteomics, the 
association of two techniques still presents a challenge (Buijs and Franklin, 2005).
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In this paper, we described an efficient “off-line” method leading to an optimize combination of 
Surface Plasmon Resonance experiments with mass spectrometry analysis on the same chip.
Biological models are Rat Serum Albumin (RSA) for the establishment of the procedure and 
sensitivity optimization and LAG-3 protein, a specific marker of human breast cancer and tuberculosis
for validation of this approach for the characterization and identification of protein complexes (Triebel 
et al., 2006). Our developments consisted in the conception and the realization of home-made protein 
chips compatible with SPR analysis. Then we presented complete on-a-chip treatments prior to mass 
spectrometry analysis with a home-made MALDI plate. Finally, all the proteins were completely 
identify by peptide mass fingerprints (PMF) and MS-MS analysis at the sub-femtomole to femtomole 
levels.
2. Materials and methods
2.1 Reagents
Rat Serum Albumine, DiThioThreitol (DTT) NH4HCO3, Acetonitrile, TriFluoroAcetic acid (TFA) 
were obtained from Sigma-Aldrich. HCCA Matrix was from Bruker Daltonics (Bremen, Germany). 
Absolute ethanol was from Carlo Erba. HBS buffer was purchased from Biacore (GE Healthcare).
Ultrapure water was produced with an Elga Instrument.
2.2 Design and fabrication of homemade chips
First, a 2 nm thick chromium (Cr) layer was deposited on a SiO2 wafer (width: 13 mm, thickness: 0.17 
mm from AGAR) with plasma sputtering technology to optimize the adherence of gold to the 
substrate. The 40 nm thick Au layer was deposited onto the top of the Cr layer using plasma sputtering 
technology. The deposition time and the argon flow pressure were optimized to obtain the theoretical 
thickness. The deposition time for the Cr and Au layers were respectively 3 and 22 sec. For all 
depositions, the argon flow pressure and current were respectively 7 µbar and 0.3 A. With these 
parameters, the deposition rates for the Au and Cr layers were respectively 109 and 60 nm/min.
2.3 Chemical functionalization & SPR experiments
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The homemade chips were chemically functionalized as follows: 
For the RSA chip, a solution of Octadecyl Mercaptan (OM), 1mM in an ethanol/water solution (4/1 by 
vol.), was sonicated for 20 minutes using Elma, (Power90W, frequency 50/60 Hz) at maximal power. 
The sensor chips were cleaned in baths of absolute ethanol then treated overnight and rinsed with ultra 
pure ethanol and water. Ultrapure water contact angles were measured with a goniometer system 
(DIGIDROP by GBX, France) with an accuracy of +/- 2°. All measurements were performed in the 
ambient atmosphere at room temperature.
For the immuno-chip, we used a self assembled monolayer composed of a mixture of 11-mercapto-1-
undecanol (11-MUOH) and 16-mercapto-1-hexadecanoic acid (16-MHA) (purchased from Sigma-
Aldrich). The mixture of 11-MUOH/16-MHA (97/3 by mole) at 1mM in absolute ethanol was 
sonicated 10 min using a sonicator Elma (Power 90W, frequency 50/60 Hz). LAG-3 protein is 
provided by Immutep SA (Châtenay Malabry, France) and is known as a prognostic indicator for 
survival of primary breast carcinomas. Monoclonal antibody A9H12 recognize specifically LAG-3 
protein and dimeric LAG-3 recombinant protein used for this study. Their molecular masses are 
160kDa both.
BIAcore experiments were performed with the Biacore™ 2000 apparatus at 25 °C with a flow rate 
comprise between 2 and 30 μl/min. According to the experiments, the running buffer was either
ultrapure water (Rathburn), saline phosphate buffer (PBS, 100mM at pH7.4 with NaCl 50mM) or HBS 
buffer. The degree of protein immobilization and the level of interactions in the Biacore technology 
apparatus were plotted on a sensorgram (response unit (RU) versus time (s)). One thousand RU 
correspond to a shift in the resonance angle of 0.1°. Calibration of the apparatus gives a correlation 
between the shift in angle and the mass, ranging from 0.1 to 1 ng/mm2, deposition on the surface of the 
biochip (Stenberg et al., 1991). After exposure to the analytical solution, the chips were then removed 
from the Biosensor unit via undock procedure with empty flow cell command. 
2.4 On-Chip Digestion
To identify the bound protein on the sensor chip, the proteins were reduced with DTT (10 min) and 
digested with trypsin. On-target tryptic digestion was performed by depositing 1 µL of 5µg/mL trypsin 
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(Trypsin Gold Mass Spectrometry Grade, PROMEGA), dissolved in 100mM NH4HCO3, pH 8.2, onto 
selected sample spots. During digestion, water was added and the chip was kept at 37°C for 10 min 
according to Terry’s procedure (Terry et al., 2004).  After digestion, the spots were dried and 1µL 
saturated HCCA in 30% acetonitrile/0.1% TFA was added to each spot using a pipette for RSA 
analysis and the matrix was not saturated (3,5 mg/ml) in 50% acetonitrile/TFA 0,1% in the case of 
protein complexes. To calibrate the mass spectrometer, standard peptides (pepmix standard peptide 
from Bruker Daltonics) were deposited onto the sample spots of the chip. The global pre-treatment is 
no longer than 30 min which warrants an entire BIA-MS study in few hours.
2.5 MALDI- TOF Mass Spectrometry
The chips were then introduced in a mass spectrometer MALDI-TOF (Ultraflex, Bruker Daltonics
Gmhb, Bremen, Germany), using a home made MALDI target. Ionisation was performed in MS and 
MS/MS (PDS-LIFT technology) by irradiation of a nitrogen laser (337 nm) operating at 50 Hz. Data 
were acquired at a maximum accelerating potential of 25kV in the positive and reflectron modes. The 
MALDI mass spectra were calibrated using the Peptide Calibration Standards from Bruker Daltonics.
The software packages Ultraflex version 3.0, Flex control, Flex Analysis and Biotools version 3.1 
were used to record and analyze the mass spectra. The database search was performed with Mascot 
(Matrix Science, London, U.K.) in the NCBI database. Peptide tolerance was set at ± 50 ppm in MS 
and ± 0.4 Da in MS/MS. Methionine oxidation was accepted as a variable modification.
3. Results- Discussion
3.1 Proof of concept of entire “on-a-chip” BIA-MS analysis of RSA at sub-femtomole per mm2
Crude gold chips were chemically functionalized with octadecyl mercaptan in order to confer the same 
properties than the HPA sensorchip® (provided by Biacore). The self-assembled monolayer (SAM)
process, obtained using a previously published procedure (Boireau et al., 2002), leads to the formation 
of a packed monolayer of OM, which confers a high degree of hydrophobicity to the chip (Fig. 1A). 
This was confirmed using contact angle measurements as summarized in Figure 1B, the average angle 
formed by small water drops onto the SAM reached 107° +/- 2°, which is close to the value expected 
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for such a substrate (Kawasaki et al., 2000). Hydrophobicity is the driving force which allows the 
adsorption of a large number of biological compounds (proteins, nucleic acids, lipids…). In our study, 
the OM layer was used as hydrophobic matrix to adsorb RSA. The adsorption process was followed in 
real time by surface plasmon resonance measurements. Briefly, the functionalized homemade chip was 
inserted into the Biacore apparatus: the response in water at 25°c and 30µl/min was measured. In order
to prepare the surface for adsorption process, it was cleaned with a pulse of organic solvent, ethanol 
(50% in water), followed by a pulse of detergent, OG (40mM). Following this procedure (i) various 
concentrations of RSA were injected onto the chip, (ii) the level of adsorption in real time was 
measured and (iii) the injection was stopped when the signal reached the expected values. The 
sensorgrams of the experiment are presented in Figures 1C, D. At high concentrations of RSA (i.e. 
above 1mg/ml) the kinetics of monolayer assembly were quick and followed by a plateau (Blondeau-
Patissier et al., 2007). The resulting protein monolayer was stable leading to an average of 1250 +/-
250 RU i.e. 19 femtomole/mm2 (Fig. 1C). It was possible to monitor the surface coverage of the RSA 
by reducing its concentration and the time of injection. That way only a small amount of RSA can be 
adsorbed and detected (theoretically up to the detection limit of the BIAcore apparatus i.e. about 0.1 
femtomole/mm2). We have performed many experiments of immobilization at low concentration 
leading to a range of surface coverage comprised between 0.7 and 5 femtomoles of RSA per mm2. An 
illustration of such experiment is given in Figure 1D where the adsorption kinetics of RSA is 
monitored at 0.1 mg/ml for 100 sec of injection and has lead to a surface coverage of 2 
femtomoles/mm2. At the end of the injection, the chip was then removed from the Biacore unit via the 
“undock” procedure with “empty flow cell” command and the gold chips are removed from the plastic 
support. 
To identify by mass spectrometry the RSA on the sensor chip, the adsorbed material was reduced and 
alkylated (see material and methods). On-target tryptic digestion was performed by depositing 100 
femtomoles of trypsin onto selected sample spots. During digestion, water was added and the chip was 
kept at 37°C for 10 min. After digestion, the spots were dried and HCCA matrix was added to each 
spot using a pipette. To calibrate the mass spectrometer, standard were deposited onto the sample 
spots of the chip. After in situ treatment of the sample, the chip is placed into a modified MALDI 
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target before being analyzed in the mass spectrometer. MALDI targets were modified in order to 
receive the chip and maintain a regular target surface. The chips were fixed with conducting sticking 
tape because MALDI targets must provide an electrically conductive surface. These two points 
guaranty good sensitivity and reproducibility for ionization over the surface of the chip and prevent
electric arcs between the target and the first lens. 
Figure 2 shows MALDI-TOF mass spectra resulting from the treatment and analysis of 0.7 
femtomole/mm2 of RSA captured and treated directly on the chip as previously described. The most 
intense peaks corresponded to the peptides generated by self-digestion of the trypsin. These trypsin 
auto-hydrolysis peaks were used for internal calibration of the spectra. In spite of the very low density 
of molecules of RSA present on the chip, the treatment is highly efficient in a short time (less than 1 
hour) and presented a rich peptide profile. Thus, twenty-three (23) peptides matched the sequence of 
RSA in submitting to the Mascot search engine. The database query allowed us to identify RSA with a 
significant score in MASCOT (Digest Matches, Score: 198). Moreover, the sequence coverage 
represented by these peptides for this protein was 36% enabling its highly reproducible identification 
by peptide mass fingerprinting at low to sub-femtomole levels.
3.2 Validation of entire “on-a-chip” BIA-MS analysis at femtomole/mm2 level of Ab/Ag couple and 
their identification by MS and MS/MS analysis.
We validated this procedure with a relevant biological model (courteously provided by Immutep SA, 
France) composed of an antibody (IgG1:A9H12) which recognize specifically the LAG3 protein a 
specific biomarker of human diseases (breast cancer and tuberculosis). In order to immobilize A9H12, 
we functionalized gold surface with a mixture of 11-mercapto-1-undecanol (11-MUOH) and 16-
mercapto-1-hexadecanoic acid (16-MHA). A scheme of the immunosensor is presented in Figure 3A. 
Briefly, the resulted self assembled monolayer presents small amount (3% by mole) of 16-MHA
molecule which bears one carboxyl group. These groups were activated using N-hydroxysuccinimide 
(NHS) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC). Immobilization of A9H12 was
mainly realized through primary amine group of lysine and the reconstitution of such immunosensor 
fit well with the Frederix’s procedure (Frederix et al., 2003). At the end of the process, the inactivation 
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of the chip was obtained with a pulse of ethanolamine and the quantification of the antibody grafting
can be done. High control on the surfacic coverage was performed according to the time of injection 
and the concentration of A9H12. Thus we are able to propose an antibody immobilization comprise 
between 1 and 10 femtomoles/mm2. In Figure 3B, four injections of A9H12 (represented with an 
asterisk) give a SPR response about 1020 RU (i.e. ≈ 6.4 femtomoles of A9H12 per mm2). We verified 
that the packed monolayer of antibody present high properties of biomolecular interactions with LAG3 
antigen (Figure 3C). For concentration above 1µM, we observed an equilibrium state leading to a 
surface density of LAG3 equivalent to the surface density in antibody (≈ 6.1 femtomoles/mm2, i.e. 
corresponding to one antigen per antibody). At this level of recognition, we stopped the SPR 
experiments and removed the chip from Biacore2000 apparatus through the “undock procedure”.
The pre-treatment procedure prior to MS experiments was similar with the one established for RSA 
identification. At the end of the process, the chip was placed on MALDI plate in order to be analyzed
and results in identifications were given in Figure 4. In spite of the presence of various proteins on the 
chip (Trypsin, A9H12 and modified LAG-3 protein), results of PMF lead to identification with high 
significance (Mascot score above 80) for both biological partners and were summarized in table 2. We 
routinely obtained high score in identification of both antibody and antigen at a level of few 
femtomoles/mm2. Thus, with this innovating and original method, we demonstrated the possibility of 
performing PMF identification of protein complexes in using exclusively an “on-a-chip” BIA-MS 
analysis. 
Moreover, in the case of protein complexes, PMF could not allow complete identifications of each 
protein and tandem mass spectrometry (MS/MS) is broadly required. We have also explored this 
analytical pathway and demonstrated that each protein could be identified by MS/MS analysis. Many 
peptides from various proteins can be fragmented in each experiment (above 4 peptides per protein for 
more than 10 chips analyzed) leading to unambiguous identification of antibody and antigen species. 
The MS/MS analysis of peptide 1374 is shown in Figure 5 and gave unambiguous LAG-3 
identification with significant Mascot score. So the rich peptide profile obtained (which could limit the 
accuracy of the analysis in the case of multiproteins complex) warrants a reservoir of peak analysable 
by tandem mass spectrometry.
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Some authors have argued that “on-a-chip” procedure could not be realistic for protein complexes
characterization and identification and recommended in fact an elution strategy (Natsume et al. 2001, 
Buijs et al., 2005). From their opinion, “on-a-chip” BIA-MS presents some limitations in regard with 
the elution way which can be summarized as follow: “on-a-chip” approach is a destructive 
investigation and the chip cannot be reused (i) and was not adapted for protein (and protein 
complexes) identification because of the large number of peptide resulting from the tryptic digestion
(ii). Our results have demonstrated that these drawbacks can be overcome:
(i) The destruction of the biochip during MS analysis is still actual but is strongly attenuated when the 
chips is produced at low cost (conception, realization and functionalization processes of the chips are 
performed in clean room and controlled laboratory environment with reduced costs).
(ii) The major drawback deals with the limitation of identification of protein complexes directly on the 
chip. This technique has been considered only helpful when the molecular mass of protein bound to 
the sensor chip is known or predicted. Most of their developments have been more purchased for 
protein detection than for protein identification (Nedelkov and Nelson, 2001, 2003). Recently, Treitz 
and co-workers have combined SAW-biosensor with MALDI-MS analysis through an “on-a-chip” 
approach (Treitz et al. 2008). However, in order to analyze deeply protein complexes on the chip, they 
performed nano-LC experiments prior to MALDI-MS at 750 femtomoles/mm2. Grote and co-workers 
presented such experiments in deposing directly on their chip few picomoles of cytochrome C 
following by a tryptic digestion and PMF analysis (Grote et al., 2005). But in this case the chip is a 
passive substrate and is disconnected from the transduction signal. The “on-a-chip” MS analysis on 
digest of protein has been poorly investigated in the past. In this paper, we demonstrated the feasibility 
in protein complexes characterization and “off-line” identification at the femtomole/mm2 level. From
our knowledge, this work is the first complete coupling between SPR and MS with entire “on-the-
chip” analysis leading to identification of protein complexes. Our global approach
(conception/realization of chips, (bio)-functionnalization of the gold surface, pre-treatments and MS 
analysis) offers a real alternative to the elution way with a similar levels of performance in sensitivity 
and accuracy.
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Recently Nedelkov has opened the way to the development of the first functional SPR-MS array 
platform (Nedelkov, 2007). These first results seem to be well suited for high-content protein 
microarrays and comprehensive protein analysis from quantitative assessment of the protein 
concentration to detection of structural protein. Our strategy could take benefit of this original 
development and could contribute to the complete automation of the protein identification and post-
transciptional modifications analysis in high throughput applications. 
4. Conclusion
We presented in this paper the developments of home-made gold biochips compatible both with the 
Biacore apparatus and with the targets of MALDI-MS instrument. These developments were based on 
the design, fabrication and functionalization of biochips compatible with Biacore experiments as well 
as the insertion of chips into MALDI targets that are compatible with the MALDI-MS instrument, the 
optimisation of “on-the-chip” sample digestion, and finally the optimization of acquisition parameters 
of MS spectra. For the first time, these developments and optimizations have made it possible to 
identify by MS and MS-MS proteins directly on the chip at femtomole and sub-femtomole levels 
without elution of bound materials. The global “on-a-chip” and “off-line” approach does not reduce 
the potential of the two methods taken independently. At contrary, this approach seems to be the 
simplest way to obtain quantitative and qualitative data for the analysis of protein complexes and 
seems to have a great potential for high throughput applications. In the near future, recent 
technological advances should enable us to continue our investigations into sensitivity and 
characterization of protein biomarkers captured in biological fluids. 
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Figure 1. SPR monitoring of RSA adsorption on OM layer. 
(A) Molecular structure of self assembled monolayer of Octadecyl Mercaptan (OM) (B) Contact angle 
measurement of small drop of water deposited on OM (C) Sensorgram (Response in RU vs Time in S) 
of the adsorption of a highly packed monolayer of RSA (1 mg/ml) on OM (1250 RU ≈ 1,25 ng/mm2
i.e. 19 fmoles/mm2). (D) Sensorgram of the adsorption of low density of RSA (0.1 mg/ml) on OM 
(130 RU ≈ 0.13 ng/mm2 i.e. 2 fmoles/mm2).
Figure 2. Peptide mass fingerprint recorded for RSA at 700 amol after biosensor capture (RSA; 
accession number gi|19705431). The inset represents 23 peptides matched out of 48 masses submitted 
to the Mascot search engine.
Figure 3. SPR monitoring of A9H12 immobilization on activated SAM and LAG-3 capture. 
(A) Scheme of the molecular structure of A9H12 immuno-chip  (B) Sensorgram (Response in RU vs 
Time in S) of the immobilization of A9H12 on 11-MUOH/16-MHA (97/3 by mole) Self Assembled 
Monolayer (1020 RU ≈ 1ng/mm2 i.e. 6 fmoles of A9H12 per mm2). (C) Sensorgram of the 
biorecognition of LAG-3 protein (980 RU ≈ 1 ng/mm2 i.e. 6 fmoles/mm2). Each injections are 
indicated with *.
Figure 4. Peptide mass fingerprint recorded for the couple A9H12/LAG3 at 6 femtomoles/mm2
(IgG 2A; accession number gi|194438) and (LAG-3; accession number gi|106885). Peptide tolerance 
was sat at +/- 50 ppm in MS analysis.
Figure 5: MS/MS analysis of fragment 1374 of LAG-3 protein with annotated b- and y-ions of 
analyzed peptide sequence RYTVLSVGPGGLR (identified residues are underlined). 
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albumin [Rattus norvegicus]  gi|19705431
Tree 
hierarchy
Meas. M/z Calc. MH+
peak 2 1019.578 1019.578
peak 3 1177.589 1177.607
peak 7 1266.627 1266.636
peak 8 1345.652 1345.697
peak 9 1374.660 1374.603
peak 11 1439.747 1439.785
peak 13 1465.707 1465.780
peak 14 1475.695 1475.655
peak 15 1482.824 1482.798
peak 16 1508.808 1508.812
peak 18 1562.798 1562.720
peak 20 1570.695 1570.699
peak 21 1609.757 1609.790
peak 23 1657.821 1657.775
peak 30 1784.799 1784.864
peak 35 1880.020 1880.035
peak 36 1891.865 1891.897
peak 38 1940.848 1940.811
peak 39 1941.937 1941.993
peak 41 1960.009 1960.050
peak 45 2265.181 2265.267
peak 46 2446.120 2446.116
peak 47 2513.232 2513.270
Range
234 - 242
25 - 34
247 - 257
299 - 310
287 - 298
439 - 452
422 - 434
222 - 233
484 - 496
230 - 242
224 - 236
104 - 117
348 - 360
118 - 130
243 - 257
439 - 456
585 - 602
106 - 122
29 - 44
435 - 452
439 - 460
265 - 286
243 - 264
Sequence
AFKAWAVAR
EAHKSEIAHR
FPNAEFAEITK
LQACCDKPVLQK
YMCENQATISSK
APQVSTPTLVEAAR
LGEYGFQNAVLVR
MKCSSMQRFGER 1: Ox (M)
LCVLHEKTPVSEK
FGERAFKAWAVAR
CSSMQRFGERAFK 4: Ox (M)
LRDNYGELADCCAK
DVFLGTFLYEYSR
QEPERNECFLQHK
MSQRFPNAEFAEITK 1: Ox (M)
APQVSTPTLVEAARNLGR
AADKDNCFATEGPNLVAR
DNYGELADCCAKQEPER
SEIAHRFKDLGEQHFK
YTQKAPQVSTPTLVEAAR
APQVSTPTLVEAARNLGRVGTK
INKECCHGDLLECADDRAELAK
MSQRFPNAEFAEITKLATDVTK 1: Ox (M)
T
Table 1: Matched peptides from MALDI-TOF measurements of 0.7 femtomoles/mm2 of 
adsorbed RSA on OM SAM digested with trypsin. Peptide tolerance was set at +/- 50 ppm.
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IgG  2A  chain  [M us m u sculu s]  gi|194438
D igest M atch es (S core: 93 .60)     
T ree h ierarch y M eas. M /z C alc . M H +
peak  1  984 .6 25 98 4 .5 84
peak  7  1140.568 1140.59 0
peak  13  1365.709 1365.74 8
peak  21  1596.817 1596.85 3
peak  28  1952.874 1952.85 8
peak  29  1956.005 1956.01 5
peak  30  1968.815 1968.85 3
peak  31  1971.928 1972.01 0
peak  33  2149.986 2149.98 3 1098
peak  34  2200.116 2200.12 2
peak  35  2227.133 2227.14 3
peak  37  2355.252 2355.23 8
peak  40  2737.378 2737.37 9
L A G 3 p rotein  p recu rsor - hu ma n   gi|106885
D igest M atch es (S core: 82 .00)
T ree h ierarch y M eas. M /z C alc . M H +
peak  3  1023.631 1023.60 6 2941 .7 87
peak  6  1138.617 1138.65 5
peak  8  1218.662 1218.68 4
peak  11  1317.698 1317.70 6 1561 .3 26
peak  14  1374.775 1374.78 5 2592 .8 45
peak  15  1395.778 1395.78 9 2409 .8 46
peak  16  1422.676 1422.70 1 4962 .0 72
peak  17  1430.707 1430.73 1 1620 .8 17
peak  19  1472.733 1472.75 3
peak  20  1488.688 1488.74 7
peak  22  1601.845 1601.86 6
peak  25  1741.880 1741.93 8
peak  26  1757.979 1757.96 7
R ange
92  - 99
100  - 110
205  - 216
203  - 216
275  - 291
227  - 243
275  - 291
227  - 243
303  - 321
184  - 202
223  - 242
223  - 243
02  - 29
R ange
111  - 119
205  - 214
99  - 110
130  - 140
98  - 110
278  - 291
380  - 391
367  - 379
166  - 180
166  - 180
128  - 140
164  - 180
128  - 141
Sequence
VD K K IE P R
G P T IK P C P PC K
V N N K D L P A P IE R
CK V N N K D L PA P IE R
N T E PV LD S D G S Y FM Y S K
A P Q V Y V L PP PE E E M T K K
NT EP V LD S D G SY FM Y S K  14: O xidation  (M )
A PQ V Y V L P PP E E E M T K K  1 4: O xidation  (M )
N SY SC SV V HE G LH N H H T T K
V V S A LP IQH Q D W M S G K E F K
G SV R APQ V Y V L P PP E E E M T K
G S V R A PQ V Y V L P PP E E E M T K K
T T APS V Y P L A P V C G D T T G SS V T L G C L VK
Sequence
SG R L P L Q P R
N R G Q G R V PV R
Y T V LSV G PG G L R
G D F SL W L R P A R
RY T V LS V G PG G L R
V GL P C R L PA G V G T R
F V W SS L D T PS Q R
L LC E V T P V S G Q E R
L G Q A SM T A SP PG SL R
L G Q A S M T A SP P G SL R  6 : O xidation (M )
QR G D F S L W L R P A R
LR L G Q AS M T AS PP G S L R
Q R G D F SL W L R P A R R
Table 2: Matched peptides from MALDI-TOF measurements of 6 femtomoles/mm2 of antigen 
LAG-3 specifically captured with the immunochip A9H12. Digestion was performed with
trypsin. Peptide tolerance was set at +/- 50 ppm.
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